Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 4

1(16.7%)

Phase 2

1(16.7%)

6Total

N/A(4)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04927702Not ApplicableTerminated

Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

Role: lead

NCT03312595Not ApplicableCompleted

Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)

Role: lead

NCT06578650Recruiting

A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms

Role: lead

NCT04918784Not ApplicableCompleted

Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers

Role: lead

NCT04405050Phase 4Withdrawn

RCT to Compare Restrata and NPWT to Heal Complex DFUs

Role: collaborator

NCT04829331Not ApplicableTerminated

Utility of Restrata With Split Thickness Skin Graft to Reconstruct the Forearm Donor Site

Role: lead

NCT04880603Phase 2Terminated

Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site

Role: collaborator

All 7 trials loaded